Oxford Biomedica plc, the leading gene and cell therapy group, has signed a new three year Development & Supply Agreement with pharmaceutical company Boehringer Ingelheim for the manufacture and supply of various types of viral vectors.
Under the terms of the agreement, Oxford Biomedica intends to manufacture GMP batches for Boehringer Ingelheim to support the development of viral vectors. The DSA also allows for the Group to manufacture and supply viral vector products in the future.
John Dawson, Chief Executive Officer of Oxford Biomedica, said: “This Development and Supply Agreement with Boehringer Ingelheim demonstrates the good progress made in our partnership with Boehringer Ingelheim, which started in 2018. We are proud to be supporting another global pharmaceutical company in the development and manufacturing of their viral vector programs.
“We now have a portfolio of partnerships spread across development of CAR-Ts, TCR-Ts and in vivo gene therapeutics, utilising lentiviral vectors. We are proud to partner with Boehringer Ingelheim, a business with proven excellence in complex manufacturing projects, as well as expertise in developing innovative medicines for patients with serious unmet medical needs.”
In January Prime Minister Rt Hon Boris Johnson MP formally Oxford Biomedica’s new 84,000 sq ft manufacturing facility Oxbox based in Oxford.